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Genome-wide association studies have successfully identified 20 
colorectal cancer susceptibility loci. Amongst these, four of the 
signals are defined by tagging single nucleotide polymorphisms 
(SNPs) on regions 14q22.2 (rs4444235 and rs1957636) and 20p12.3 
(rs961253 and rs4813802). These markers are located close to two 
of the genes involved in bone morphogenetic protein (BMP) sign-
aling (BMP4 and BMP2, respectively). By investigating these four 
SNPs in an initial cohort of Spanish origin, we found substantial 
evidence that minor allele frequencies (MAFs) may be different 
in northern and southern European populations. Therefore, we 
genotyped three additional southern European cohorts compris-
ing a total of 2028 cases and 4273 controls. The meta-analysis 
results show that only one of the association signals (rs961253) 
is effectively replicated in the southern European populations, 
despite adequate power to detect all four. The other three SNPs 
(rs4444235, rs1957636 and rs4813802) presented discordant 
results in MAFs and linkage disequilibrium patterns between 
northern and southern European cohorts. We hypothesize that 
this lack of replication could be the result of differential tagging 
of the functional variant in both sets of populations. Were this 
true, it would have complex consequences in both our ability to 
understand the nature of the real causative variants, as well as for 
further study designs. 
Introduction
Colorectal cancer (CRC) is one of the major forms of cancer, being 
the second most frequent neoplasm in both sexes and one of the most 
important morbidity causes in the first world (1). The genetic contribu-
tion to CRC has been estimated to be around 35% by twin studies (2). 
However, high-risk germline variants that cause hereditary syndromes 
can only explain up to 5% of the disease cases, and it seems that much 
of the heritable risk could be due to multiple low-penetrance alleles 
appearing frequently in the general population, and each conferring a 
modest effect on disease risk (3–6).
In this context, the implementation of association studies to 
genome-wide levels has successfully allowed for the identification 
of 20 of these low-penetrance loci associated with CRC risk in the 
form of tagging single nucleotide polymorphisms (SNPs) (7–9). 
Notably, at least four of these signals (14q22.2, 15q13.3, 20p12.3 and 
20q13.3) are close to genes that are members of the bone morpho-
genetic protein (BMP) signaling pathway. Members of this pathway 
have been proven to interact with transforming growth factor-β effec-
tors, thereby playing an essential role in colonic cell signal transduc-
tion and CRC development (10,11). It is currently believed that BMP 
signaling is related to CRC development through an increase in stem 
cell numbers near colorectal crypt bases, thus elevating the number 
of cells susceptible to tumor-causing mutations (12). The importance 
of this pathway is surely reflected on the fact that up to seven SNPs 
have been related to CRC susceptibility through genome-wide asso-
ciation studies: rs4444235 and rs1957636 with BMP4, rs961253 and 
rs4813802 with BMP2, rs16969681 and rs11632715 with GREM1 
and rs4939827 with SMAD7 (7,8,13).
Thus, we genotyped the four SNPs at 14q22.2 and 20p12.3 in order 
to ascertain their relationship with CRC in a cohort of 1449 cases 
and 1450 controls of Spanish origin. These four markers have so far 
shown the most strongly associated signals with the CRC phenotype 
and, importantly, there had been no studies to the date on their rel-
evance in southern European populations.
To our knowledge, this was the first attempt to evaluate these signals 
in a southern European population. Because we found substantial evi-
dence of discrepancies at allele frequencies with the already described 
sample sets, we later decided to additionally genotype the four mark-
ers in three supplementary cohorts from Spain, Italy and Portugal, so 
as to further evaluate this potential north–south divergence.
Materials and methods
Samples and populations
EPICOLON cohort. Subjects were 1449 cases [870 males, mean age at 
diagnosis 73  years; standard deviation (SD) ± 0.70] and 1000 controls 
ascertained through the EPICOLON  project and 450 additional controls 
Abbreviations:  BMP, bone morphogenetic protein; CRC, colorectal cancer; 
LD, linkage disequilibrium; MAF, minor allele frequency; OR, odds ratio; SD, 
standard deviation; SNP, single nucleotide polymorphisms.
†All members are listed in a Supplementary Note.








/carcin/article/34/2/314/2464202 by na user on 02 February 2021
CRC BMP susceptibility SNPs in European populations
from the Spanish National DNA bank (http://www.bancoadn.org/). The 
EPICOLON Consortium comprises a prospective, multicentre and popula-
tion-based epidemiology survey of the incidence and features of CRC in the 
Spanish population (14,15). Cases were selected as patients with de novo 
histologically confirmed diagnosis of colorectal adenocarcinoma. Controls 
were confirmed to have no cancer or history of neoplasm and no family 
history of CRC. They were matched with cases for hospital, sex and age 
(±5 years).
SPAIN2 cohort. Samples were 801 CRC patients (544 males, mean age at 
diagnosis 69.6 years; SD ± 0.59) recruited through a toxicology study from 
four different hospitals spread across the Spanish territory, and an additional 
105 cases and 1287 controls (816 males, mean age 50.1 years; SD ± 7.2) from 
the Spanish National DNA bank.
Italian cohort. Subjects were 622 CRC cases (379 males, mean age at 
diagnosis 64 years; SD ± 11.3) and 2486 blood donors (907 males, mean 
age at donation 44 years; SD ± 12.2). The cases are from a series of con-
secutive individuals affected with CRC who underwent surgery at the 
Fondazione IRCCS Istituto Nazionale Tumori in Milan starting October 
2005. The 2486 normal controls were blood donors recruited through the 
Immunohematology and Transfusion Medicine Service of Fondazione 
IRCCS Istituto Nazionale Tumori and the Associazione Volontari Italiani 
Sangue Comunale in Milan.
Portuguese cohort. Samples were 495 CRC and 5 colorectal adenomas 
patients (235 males, mean age at diagnosis 51 years; SD ± 11.81). About four-
fifths of the patients were recruited according to the Bethesda or Amsterdam 
criteria for Lynch syndrome and had a negative genetic testing. The remain-
ing patients were recruited with diagnosis of either CRC at <75 years old, or 
an ‘advanced’ colorectal adenomas (villous histology, or >1 cm diameter or 
severe dysplasia at <60 years old). The 500 controls (269 males, mean age 
at donation 47; SD ± 8.7) were blood donors recruited from the Portuguese 
Oncology Institute of Porto. 
DNA was obtained from peripheral blood by standard extraction proce-
dures. Sample collection was undertaken with informed consent and ethical 
review board approval of the corresponding institution, in accordance with the 
tenets of the Declaration of Helsinki.
SNP genotyping and quality control
The Spanish EPICOLON and SPAIN2 cohorts were genotyped using 
MassARRAY iPLEX technology (Sequenom, San Diego, CA). Italian (13) 
and Portuguese samples were genotyped with the KASPar SNP Genotyping 
system (KBioscience, Herts, UK). Samples with genotyping success rates 
<95% were removed from the study with the help of PLINK v1.7 (16). Hardy-
Weinberg equilibrium in controls was also ensured (at an α < 0.05) in order 
to avoid genotyping errors and detect any hidden population stratification. 
Duplicate samples were included in each plate of the initial stage (up to 5% 
of the total samples of the EPICOLON cohort) to ensure genotyping accuracy. 
All samples with concordance rates <100% were removed from further analy-
ses. Additionally, HapMap samples were also included during MassARRAY 
genotyping to avoid genotyping errors.
MAF analysis, 1000 Genomes data, LD mapping and statistics
Welch’s two-tail statistic (a modification of Student’s t-test assuming 
different variances between groups), as implemented in R, was used to 
test for differences between minor allele frequencies (MAFs) amongst the 
described populations (northern populations versus EPICOLON; northern 
versus southern populations) (17). The same test was used to check 
for differences in data retrieved from the 100 Genomes Phase I (MAFs) 
between the Utah residents with northern and western european ancestry 
(CEU)/Finnish in Finland (FIN)/ British in England and Scotland (GBR) 
group of populations and Iberian population from Spain (IBS)/Toscans 
in Italy (TSI)/EPICOLON  (controls) using the data from 1000 Genomes 
Phase I retrieved with the help of the online tool SPSmart (http://spsmart.
cesga.es/) (18). Linkage disequilibrium (LD) blocks were inspected using 
the HapMap3 r2 CEU and TSI populations (no other European populations 
were available at the time) with the help of Haploview v4.2 (19,20). The 
ability for these four SNPs to capture the association signal was evaluated by 
comparing the list of markers closely related at different r2 values (0.8 down 
to 0.5) for both populations. Allelic frequencies and odds ratio (OR) with 
95% confidence intervals were calculated for each population with PLINK 
v1.7 (16). Cochran’s Q statistic and I2 coefficients were also calculated to 
measure heterogeneity between the southern cohorts in order to decide 
whether to use a fixed or random-effect meta-analysis model (21,22). Large 
heterogeneity was typically defined as I2 ≥ 75%. Power was calculated with 
CaTS power calculator (23).
Data from the northern European cohorts were obtained from Tomlinson 
et al. (2011) (13). OR comparisons between northern and southern European 
data sets were evaluated by logistic regression with the help of the SUEST tool 
in STATAv12 (Stata Corp., TX, Texas).
Results
After genotyping the four SNPs (rs4444235, rs1957636, rs961253 
and rs4813802) in our initial Spanish cohort, we found that MAFs 
in EPICOLON departed from the proportions described for several 
populations in the literature (Table I). The differences in MAFs were 
significant in all four SNPs for the case and control groups. Given 
these results and the fact that all the previously reported populations 
had a northern European origin, we decided to further explore this 
potential heterogeneity between northern and southern European pop-
ulations for complementary evidence. By these means, we searched 
the 1000 Genomes data for the estimated MAFs for these markers 
(Table II) (18). We observe that in this case, the differences for the 
northern versus southern European MAFs are not statistically signifi-
cant, a fact that could also be due to the low sample sizes of some of 
the populations.
LD blocks (±100 kb regions from each marker) were also checked 
for the 14q22.2 and 20p12.3 regions in the CEU and TSI popula-
tions separately. Overall, there were no great visible differences in 
the block patterns (taken as D′ pairwise measures) between these 
populations (Supplementary Figures 1–4, available at Carcinogenesis 
Online). Fine resolution LD screenings, however, revealed that at least 
rs4444235 and rs1957636 at 14q22.2 showed different tagging abili-
ties in both populations (Table III).
SNP genotyping in other cohorts
With the results obtained in the initial comparisons, we decided 
to additionally genotype other southern European cohorts, in 
Table I. MAF differences between EPICOLON and the northern European 
populations
SNP/locus/minor allele Cohort MAF cases MAF controls
rs4444235 Tomlinson et al. (13)  
averagea
0.484 0.457
Chr14: 54,410,919 EPICOLON 0.556 0.537
C Welch test P-value 
(Tomlinson et al.  
versus EPICOLON)
4.251E-11* 1.084E-10*
rs1957636 Tomlinson et al. (13)  
averagea
0.421 0.398
Chr14:54,560,018 EPICOLON 0.407 0.394
A Welch test P-value 
(Tomlinson et al.  
versus EPICOLON)
2.729E-03* 0.01356*
rs961253 Tomlinson et al. (13)  
averagea
0.380 0.353
Chr20:6,404,281 EPICOLON 0.350 0.333
A Welch test P-value 
(Tomlinson et al.  
versus EPICOLON)
1.810E-05* 3.506E-03*
rs4813802 Tomlinson et al. (13)  
averagea
0.382 0.360
Chr20:6,699,595 EPICOLON 0.319 0.321




Frequencies in case and control groups are shown for each of the cohorts, as 
well as Welch’s statistic P-value. Note that for rs4444235, frequencies are 
shown always for the C allele, even though it does not constitute the minor 
allele for some of the cohorts.
aCorresponds to the average values for the MAFs present in the study by 
Tomlinson et al. (13); these are UK1, Scotland1, UK2, Scotland2, VQ58, 
CCFR, Australia, Helsinki, Cambridge, COIN/NBS UK3, Scotland3 and 
UK4.
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order to obtain more data and have more reliable results regard-
ing the differences that we had observed. Therefore, we geno-
typed a total of 2028 cases and 4273 controls from three new 
cohorts: the Spanish SPAIN2 cohort, the Italian ITALY cohort 
and the Portuguese PORTUGAL cohort. The results from this 
second genotyping round are illustrated in Table IV. Briefly, SNPs 
rs1957636, rs961253 and rs4813802 showed higher frequen-
cies in northern compared with southern European populations, 
whereas the opposite was observed for rs4444235. All MAF com-
parisons between northern and southern European populations 
remained significant, with the exception of the rs961253 cases 
group, which is probably influenced by the outlier result from the 
SPAIN2 cohort being similar to the values for the previous nor-
thern European populations.
Once the MAF comparisons were made, we also performed the 
association analyses for each of the four markers in the southern 
European data sets both individually and altogether. We found that the 
only association signal that could be effectively replicated was that of 
rs961253 (meta-analysis P = 0.010; OR = 1.091). None of the other 
three signals tagged by markers rs4444235, rs1957636 and rs4813802 
could be replicated in the southern European data sets, despite our 
study being powered enough to detect them (>80%). OR from the 
meta-analysis of the four populations were consistent in directions 
with the ones described in the literature for each of the SNPs. However, 
Table II. Allele frequencies for the four SNPs in the 1000 Genomes 
SNP Chr Position Allele Population N MAF Welch t-test (CEU/FIN/GBR versus 
EPICOLONCT
a/IBS/TSI)




















Frequencies for the 1000 Genomes northern (CEU, FIN and GBR) and southern (IBS and TSI) populations.
aEPICOLONCT: EPICOLON controls as depicted in Table I.
Table III. LD patterns for each of the four SNPs in HapMap CEU compared 
with TSI
SNP CEU TSI
r2 Tagged SNPs r2 Tagged SNPs
rs4444235 >0.7 rs17563 >0.7
rs2071047
>0.5 >0.5 rs12587398
rs1957636 >0.8 >0.8 rs7160450
>0.7 >0.7 rs12887156
rs1953743
>0.6 rs7149949 >0.6 rs12892552
rs7492415
rs961253 >0.8 to >0.5 No differences >0.8 to >0.5 No differences
rs4813802 >0.8 to >0.5 No differences >0.8 to >0.5 No differences
Tagging relationships between rs4444235, rs1957636, rs961253 and 
rs4813802 for different r2 thresholds (0.8 down to 0.5) and their relationship 
with LD patterns. Only r2 values with differential tagging have been included 
for visualization purposes.
Table IV. MAF values for the four SNPs in the southern European cohorts
SNP/minor allele Cohort MAF cases MAF controls




Welch test P-value 
(Tomlinson et al.a versus 
southernb)
1.036E-07* 2.417E-06*




Welch test P-value 
(Tomlinson et al.a versus 
southernb)
9.873E-03* 0.01444*




Welch test P-value 
(Tomlinson et al.a versus 
southernb)
0.07824 8.284E-04*




Welch test P-value 
(Tomlinson et al.a versus 
southernb)
7.397E-03* 8.816E-05*
Allele frequencies in each EPICOLON, SPAIN2, ITALY and PORTUGAL 
are depicted for comparison purposes with Table I. 
aCorresponds to the average values for the MAFs present in the study by 
Tomlinson et al. (13); these are UK1, Scotland1, UK2, Scotland2, VQ58, 
CCFR, Australia, Helsinki, Cambridge, COIN/NBS UK3, Scotland3 and 
UK4.
bSouthern: southern European populations (EPICOLON, SPAIN2, ITALY 
and PORTUGAL).
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rs4813802 proved to have significant differences between OR in the 
northern and southern European cohorts (P = 0.036) (Table V).
Discussion
SNPs rs4444235 and rs1957636 on chromosome 14q22.2, and 
rs961253 and rs4813802 on 20p12.3 have been related to CRC sus-
ceptibility in previous association studies (13). Although their rela-
tionship with CRC risk has been undoubtedly established, all of the 
cohorts described so far happened to have a northern European origin. 
Thus, we thought it would be interesting to study the behavior of these 
SNPs and their related association signals in an independent case-con-
trol series of southern European origin (EPICOLON). The discrep-
ancies between EPICOLON and the northern European populations 
further justified the latter inclusion of three new cohorts (SPAIN2, 
ITALY and PORTUGAL) in the analyses.
We found that allele frequencies at the four investigated SNPs were 
significantly different between northern and southern European popu-
lations. This divergence was observable both when comparing MAFs 
between the northern described populations and EPICOLON, and to a 
lesser extent for the 1000 Genomes European data available for these 
markers. LD block analysis performed separately for the CEU and 
TSI HapMap3 populations at both the broad and fine levels was less 
conclusive. The fine scale analysis shows some evidence of variation 
in the tagging abilities of the two SNPs close to BMP4 (rs4444235 
and rs1957636). This is an important point, because in order for these 
association signals to be replicated in other cohorts, the allelic archi-
tecture of the populations, namely LD structure, needs to be shared 
(24). Given these differences, it is easy to understand why only one of 
these signals (rs961253) could be positively replicated in the associa-
tion analysis in either the four populations separately or their meta-
analysis (despite the study being powered enough to detect all four).
It is important to note that each of the markers represents an inde-
pendent association signal with its own distinctive features and dif-
ferent evidence of discrepancy between the northern and southern 
European cohorts. For instance, rs4444235 shows significant MAF 
discrepancies amongst the northern and southern European cohorts 
at each stage of this investigation. Furthermore, markers tagged 
by rs4444235 are different in the CEU and TSI HapMap3 popu-
lations (Table III). This is also true of rs1957636. For rs4813802, 
the evidence of differential behavior between northern and south-
ern populations in further supported by the fact that ORs seem to 
be significantly different for both groups. It is interesting that the 
only replicated association signal (that of rs961253) shows much 
weaker evidence of differences between the northern and southern 
European data sets. MAFs are not significantly different in northern 
and southern European cases when all southern European cohorts 
are considered together. Also, the LD analysis shows that rs961253 
tags the same markers in CEU and TSI populations (Table III), hence 
explaining our ability to replicate this association in the southern 
European cohorts.
The differences observed in allele frequencies as well as the lack of 
replication for the association signals in the southern European cohorts 
may arise from a variety of scenarios, each of which may apply to 
either one of the three unreplicated markers: (i) tagging of the real 
causative variant may be different in northern and southern European 
populations, with this ‘imperfect’ tagging resulting in the underesti-
mation of the effect of the real functional variant; (ii) although the 
Common Disease–Common Variant hypothesis is thought to explain 
a wide proportion of disease heritability, we cannot rule out the pos-
sibility that other types of genetic variation, namely rarer variants, are 
responsible for these association signals (25); (iii) although the least 
probable, the assumption that the susceptibility variants are the same 
in all European populations is not necessarily true, and therefore, it 
could be the case that the variants tagged in the northern cohorts do 
not constitute CRC risk factors in the southern populations. The case 
might be a little different for rs4444235 however. It has been discov-
ered that this variant may have some direct implications in the cis-
regulation of BMP4, and thus situations (i) and (ii) are not applicable 
for this marker (26). Therefore, we can only assume that in this case 
either the described OR has been underestimated and much larger 
cohorts are needed to detect this subtle effect, or that it does indeed 
not constitute a CRC risk variant in the studied southern European 
populations.
Although Europe is thought to be overall homogeneous, it has 
already been widely documented that there are two north–south west–
east gradients that determine the genetic diversity of European popu-
lations (27,28). These differences between the northern and southern 
European populations are compatible with previous theories that have 
postulated a southeast–northwest expansion in the continent or larger 
effective population sizes in southern than northern Europe (with the 
possible exception of population isolates, such as the Finns) (29). This 
is also supported by the fact that genetic diversity tends to be larger 
and LD smaller in southern Europe (30). Therefore, allele frequencies 
may vary greatly between populations for some particular loci, due 
to founder effects and genetic drift, and this may make some SNPs 
informative in one population but not in another. This fact has some 
important implications in association studies, where mismatches in 
ancestry between cohorts may lead to false-positive findings or a 
decreased power to detect associations (31).
Our results suggest that although other CRC susceptibility loci 
(8q23.3, 10p14, 11q23 and 15q13.3) have been described to behave 
similarly in all the cohorts studied (13,32,33), European popula-
tions may not be as homogeneous as initially thought for the three 
unreplicated loci with regards to CRC susceptibility. Whatever the 
underlying reason for these differences may be, we must highlight 
that these could have some serious implications in further fine-map-
ping, signal-refining or functional works and should be taken into 
account in subsequent study designs when considering these loci. 
The eventual finding of the real causative variants may be the key 
to fully understand the reason differences such as those described 
in this study. Clarification of CRC association signals and their 
Table V. Association values for the southern European cohorts








Meta-analysis Tomlinson  
et al. (13) 
Tomlinson et al.  
(13) OR versus 
southern OR
OR P OR P OR P OR P OR I2 P OR P
rs4444235 C 1.049 0.391 0.967 0.591 1.038 0.585 1.032 0.722 1.021 0.00 0.533 1.091 0.300
rs1957636 A 1.065 0.260 1.036 0.565 0.993 0.908 1.091 0.350 1.041 0.00 0.219 1.084 0.167
rs961253 A 1.078 0.197 1.252 5.656E-04* 0.942 0.388 1.109 0.255 1.091 66.83 0.010* 1.117 0.993
rs4813802 G 1.008 0.899 1.065 0.337 0.881 0.075 1.154 0.137 1.009 52.07 0.798 1.093 0.036*
P-values and ORs are shown for each population independently plus the meta-analysis of all four southern European populations. The last column corresponds 
to the P-value for OR comparisons between the northern and southern European populations for each of the markers. Numbers in brackets below the cohort 
correspond to number of cases and controls. The last column shows the P-value for the test comparing the OR between the Tomlinson et al. (13) report and the 
results from the meta-analysis of our four southern European populations.
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behavior in both northern and southern European populations could 
be extremely helpful in the detection of individuals at higher risk of 
developing CRC.
Supplementary material
Supplementary Figures 1–4 can be found at http://carcin.oxfordjour-
nals.org/
Funding
Fondo de Investigación Sanitario/FEDER (08/1276, 08/0024, 
PS09/02368, 11/00219 and 11/00681); Instituto de Salud 
Carlos III (Accion Transversal de Cancer); Xunta de Galicia 
(PGIDIT07PXIB9101209PR); Ministerio de Economía y 
Competitividad (SAF07-64873 and SAF2010-19273); Fundación 
Privada Olga Torres (C.R.P.). C.F.R.  and S.C-B.  are supported 
by grants from Fondo de Investigación Sanitaria (PS09/02368 to 
C.F.R. and CP03/0070 to S.C-B.); A.Car., M.T., S.C-B., L.C.C. and 
I.T. are supported by the FP7 CHIBCHA Consortium.
Acknowledgements
We are sincerely grateful to all patients who participated in this study, recruited 
as part of the EPICOLON Project. We acknowledge the Spanish National 
DNA bank (BNADN) for the availability of the samples. We also thank all the 
individuals who participated to the Italian study and the personnel of Tissue 
Bank of Fondazione IRCCS Istituto dei Tumori for sample collection and all 
pathologists for their contribution and collaboration.
Conflict of Interest Statement: None declared. 
References
 1. Ferlay,J. et al. (2004) GLOBOCAN 2002: cancer incidence, mortality and 
prevalence worldwide. IARC Cancer Base No. 5, version 2.0, IARC, Lyon.
 2. Lichtenstein,P. et  al. (2000) Environmental and heritable factors in the 
causation of cancer–analyses of cohorts of twins from Sweden, Denmark, 
and Finland. N. Engl. J. Med., 343, 78–85.
 3. de la Chapelle,A. (2004) Genetic predisposition to colorectal cancer. Nat. 
Rev. Cancer, 4, 769–780.
 4. Aaltonen,L.A. (2000) Hereditary intestinal cancer. Semin. Cancer Biol., 
10, 289–298.
 5. Castells,A. et al. (2009) Concepts in familial colorectal cancer: where do 
we stand and what is the future? Gastroenterology, 137, 404–409.
 6. Houlston,R.S. et al. (2004) The search for low-penetrance cancer suscepti-
bility alleles. Oncogene, 23, 6471–6476.
 7. Houlston,R.S. et al. (2008) Meta-analysis of genome-wide association data 
identifies four new susceptibility loci for colorectal cancer. Nat. Genet., 40, 
1426–1435.
 8. Houlston,R.S. et  al. (2010) Meta-analysis of three genome-wide associ-
ation studies identifies susceptibility loci for colorectal cancer at 1q41, 
3q26.2, 12q13.13 and 20q13.33. Nat. Genet., 42, 973–977.
 9. Dunlop,M.G. et  al. (2012) Common variation near CDKN1A, POLD3 
and SHROOM2 influences colorectal cancer risk. Nat. Genet., 44, 
770–776.
 10. Deng,H. et al. (2007) Bone morphogenetic protein-4 is overexpressed in 
colonic adenocarcinomas and promotes migration and invasion of HCT116 
cells. Exp. Cell Res., 313, 1033–1044.
 11. Deng,H. et  al. (2009) Overexpression of bone morphogenetic protein 4 
enhances the invasiveness of Smad4-deficient human colorectal cancer 
cells. Cancer Lett., 281, 220–231.
 12. He,X.C. et  al. (2004) BMP signaling inhibits intestinal stem cell self-
renewal through suppression of Wnt-beta-catenin signaling. Nat. Genet., 
36, 1117–1121.
 13. Tomlinson,I.P. et al. (2011) Multiple common susceptibility variants near 
BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing 
heritability of colorectal cancer. PLoS Genet., 7, e1002105.
 14. Piñol,V. et  al. (2005) Accuracy of revised Bethesda guidelines, micro-
satellite instability, and immunohistochemistry for the identification of 
patients with hereditary nonpolyposis colorectal cancer. JAMA, 293, 
1986–1994.
 15. Fernández-Rozadilla,C. et al. (2010) Single nucleotide polymorphisms in 
the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort. 
PLoS ONE, 5(9), e12673. 
 16. Purcell,S. et  al. (2007) PLINK: a tool set for whole-genome associ-
ation and population-based linkage analyses. Am. J.  Hum. Genet., 81, 
559–575.
 17. Ihaka,R. et  al. (1996) R: a language for data analysis and graphics. J. 
Comput. Graph Stat., 5, 299–314.
 18. 1000 Genomes Project Consortium. (2010) A map of human genome vari-
ation from population-scale sequencing. Nature, 467, 1061–1073.
 19. International HapMap Consortium. (2007) A second generation human 
haplotype map of over 3.1 million SNPs. Nature, 449, 851–861.
 20. Barrett,J.C. (2009) Haploview: visualization and analysis of SNP genotype 
data. Cold Spring Harb. Protoc., 10, pdb.ip71.
 21. Petitti,D.B. (2000) Meta-analysis, Decision Analysis, and Cost-
effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 
Oxford University Press, New York, NY.
 22. Higgins,J.P. et  al. (2002) Quantifying heterogeneity in a meta-analysis. 
Stat. Med., 21, 1539–1558.
 23. Skol,A.D. et  al. (2006) Joint analysis is more efficient than replication-
based analysis for two-stage genome-wide association studies. Nat. Genet., 
38, 209–213.
 24. Houlston,R.S. (2012) COGENT (COlorectal cancer GENeTics) revisited. 
Mutagenesis, 27, 143–151.
 25. Weiss,K.M. et al. (2000) How many diseases does it take to map a gene 
with SNPs? Nat. Genet., 26, 151–157.
 26. Lubbe,S.J. et al. (2012) The 14q22.2 colorectal cancer variant rs4444235 
shows cis-acting regulation of BMP4. Oncogene, 31, 3777–3784.
 27. Heath,S.C. et  al. (2008) Investigation of the fine structure of European 
populations with applications to disease association studies. Eur. J. Hum. 
Genet., 16, 1413–1429.
 28. Seldin,M.F. et al. (2006) European population substructure: clustering of 
northern and southern populations. PLoS Genet., 2, e143.
 29. Cavalli-Sforza,L.L. et  al. (1993) Human genomic diversity in Europe: 
a summary of recent research and prospects for the future. Eur. J. Hum. 
Genet., 1, 3–18.
 30. Lao,O. et al. (2008) Correlation between genetic and geographic structure 
in Europe. Curr. Biol., 18, 1241–1248.
 31. Novembre,J. et al. (2008) Genes mirror geography within Europe. Nature, 
456, 98–101.
 32. Tomlinson,I.P. et  al. (2008) A genome-wide association study identifies 
colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. 
Nat. Genet., 40, 623–630.
 33. Pittman,A.M. et al. (2008) Refinement of the basis and impact of common 
11q23.1 variation to the risk of developing colorectal cancer. Hum. Mol. 
Genet., 17, 3720–3727.








/carcin/article/34/2/314/2464202 by na user on 02 February 2021
